Previous 10 | Next 10 |
CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in a fi...
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics PR Newswire Quotient's Somatic Genomics platform reveals new approaches to treat disease based on the vast genetic variation present in the body's trilli...
CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in a fi...
First-ever demonstration of sustained pre-transcriptional upregulation of gene expression by an epigenomic controller in both in vitro and in vivo models of liver fibrosis Single epigenomic controller demonstrated ability to simultaneously regulate the expression of chemokines CXCL9-11 ...
Omega Therapeutics Inc. (OMGA) is expected to report $-0.56 for Q3 2023
2023-11-09 13:32:26 ET More on Omega Therapeutics Biggest stock movers today: Sirius XM, United Natural Foods, Immunovant and more Omega slips after early data for lead candidate in solid tumors Seeking Alpha’s Quant Rating on Omega Therapeutics Histor...
Announced promising preliminary clinical data for OTX-2002 from ongoing MYCHELANGELO™ I trial; clinical proof-of-platform established with potential applicability across a broad range of diseases Advanced OMEGA platform capabilities and presented new preclinical data on multiple ...
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in...
2023-11-02 13:15:49 ET More on etc. Dynatrace, Inc. (DT) Q2 2024 Earnings Call Transcript Geron Corporation 2023 Q3 - Results - Earnings Call Presentation Gates Industrial: Encouraging Q3 Report Needed To Finally Create A Floor For The Stock Icahn Enterprises...
Coordinated modulation of epigenetic profile of CXCL1-8 genes with corresponding downregulation of gene expression and protein levels, and inhibition of immune cell recruitment, shown in multiple models of inflammatory disease Demonstrates OMEGA platform’s ability to prospectively ...
News, Short Squeeze, Breakout and More Instantly...
Omega Therapeutics Inc. Company Name:
OMGA Stock Symbol:
NASDAQ Market:
CAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the election of Richard N. Kender to its...
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fires...
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Kaan Certel, Ph.D., as...